Q-omics provides the consensus-scored ASAP1-IT2 profile across patient tissues and cancer cell-line models. ASAP1-IT2 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ASAP1-IT2 is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, ASAP1-IT2 RNA expression shows 14,508 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, HNSC, and UVM as cancer lineages where ASAP1-IT2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ASAP1-IT2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ASAP1-IT2 survival associations across molecular data types. ASAP1-IT2 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ASAP1-IT2 RNA expression–survival associations across cancer types. High ASAP1-IT2 expression shows unfavorable associations in KIRC, ACC, LIHC, UVM and THCA, but favorable associations in BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ASAP1-IT2 RNA expression.
This table summarizes ASAP1-IT2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for ASAP1-IT2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ASAP1-IT2 shows higher tumor expression in HNSC, KIRC, STAD, LIHC, READ and CHOL. The HNSC box plot shows higher ASAP1-IT2 RNA expression in tumor versus normal tissue (log2 FC = +0.109, t-test p < 0.001).
This table shows molecular features associated with ASAP1-IT2 in patient tissues and cancer cell lines. In patient samples, ASAP1-IT2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
